{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:22:09Z","timestamp":1772119329602,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>BCR::ABL1-negative myeloproliferative neoplasms are chronic diseases characterized by high symptom burden due to systemic inflammation. Treatment objectives include cytoreduction and alleviation of symptoms. Besides standard therapies, complementary and alternative medicine (CAM) methods are frequently used and requested by cancer patients. Aim of this study was to assess the interest in and use of CAM by patients diagnosed with MPN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was conducted as a patient-reported, paper-and-pencil-based questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      166 patients with MPN were included, 72 (43.4%) male and 94 (56.6%) female. Median age was 65.0 years. Diagnoses included ET 66\/166 (39.8%), PV 40\/166 (24.1%), MF 51\/166 (30.7%) MPN-U 8\/166 (4.8%) and SM-AHN 1\/166 (0.6%). Overall, more frequent use of CAM was documented in females (59.6%) compared to males (41.7%),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022. A significant proportion of patients reported on the ingestion of nutritional supplements: 44\/163 (26.5%) vitamin D, 26\/165 (15.7%) vitamin C, 19\/165 (11.4%) zinc, 13\/165 (7.8%) secondary plant products, 12\/165 (7.2%) selenium, and 19\/165 (11.4%) multivitamin preparations. Regarding other CAM-related measures: 5\/164 (3.0%) used amygdalin, 4\/164 (2.4%) mistletoe therapy, 11\/165 (6.6%) acupuncture, 6\/165 (3.6%) homeopathy, 11\/165 (6.6%) yoga, 10\/165 (6%) reported receiving spiritual support, while 3\/165 (1.8%) used the services of \u201chealers\u201d. A higher rate of CAM use was found among patients with longer disease duration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Use of CAM was recorded in the majority of patients with MPN. Higher use of CAM-related measures was reported by women and patients with longer disease duration. Patients should be regularly consulted about the use of CAM, its risks should be considered and pointed out, and safe methods should be recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-025-06421-5","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:49:29Z","timestamp":1768927769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias"],"prefix":"10.1007","volume":"152","author":[{"given":"Carl C.","family":"Crodel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Kohnle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus P.","family":"Radsak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"N\u00fcckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Jilg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutta","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"20","key":"6421_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"4","key":"6421_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2310\/7200.2006.019","volume":"4","author":"JA Astin","year":"2006","unstructured":"Astin JA, Reilly C, Perkins C, Child WL, Susan G. Komen Breast Cancer Foundation (2006) Breast cancer patients\u2019 perspectives on and use of complementary and alternative medicine: a study by the Susan G. Komen Breast Cancer Foundation. J Soc Integr Oncol 4(4):157\u201369. https:\/\/doi.org\/10.2310\/7200.2006.019","journal-title":"J Soc Integr Oncol"},{"issue":"2","key":"6421_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A (2018) The 2016 who classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8(2):15. https:\/\/doi.org\/10.1038\/s41408-018-0054-y","journal-title":"Blood Cancer J"},{"issue":"6","key":"6421_CR4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","volume":"148","author":"G Barosi","year":"2010","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European Leukemianet (ELN) consensus process. Br J Haematol 148(6):961\u2013963. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08019.x","journal-title":"Br J Haematol"},{"issue":"2","key":"6421_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00280-023-04504-z","volume":"91","author":"WJ Chan","year":"2023","unstructured":"Chan WJ, Adiwidjaja J, McLachlan AJ, Boddy AV, Harnett JE (2023) Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance. Cancer Chemother Pharmacol 91(2):103\u2013119. https:\/\/doi.org\/10.1007\/s00280-023-04504-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"6421_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1067\/mcp.2000.112240","volume":"68","author":"D D\u00fcrr","year":"2000","unstructured":"D\u00fcrr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John's Wort induces intestinal P-glycoprotein\/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68(6):598\u2013604. https:\/\/doi.org\/10.1067\/mcp.2000.112240","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"6421_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s13187-019-1480-7","volume":"35","author":"H Eisfeld","year":"2020","unstructured":"Eisfeld H, Bauer F, Dubois C, Schmidt T, Kastrati K, Hochhaus A, H\u00fcbner J (2020) Importance of and satisfaction with information about their disease in cancer patients. J Cancer Educ 35(2):403\u2013411. https:\/\/doi.org\/10.1007\/s13187-019-1480-7","journal-title":"J Cancer Educ"},{"issue":"4","key":"6421_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.clpt.2004.06.007","volume":"76","author":"RF Frye","year":"2004","unstructured":"Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ (2004) Effect of St John\u2019s wort on Imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76(4):323\u2013329. https:\/\/doi.org\/10.1016\/j.clpt.2004.06.007","journal-title":"Clin Pharmacol Ther"},{"issue":"24","key":"6421_CR9","doi-asserted-by":"publisher","first-page":"9445","DOI":"10.1002\/cam4.3566","volume":"9","author":"K Gowin","year":"2020","unstructured":"Gowin K, Langlais BT, Kosiorek HE, Dueck A, Millstine D, Huberty J, Eckert R, Mesa RA (2020) The SIMM study: survey of integrative medicine in myeloproliferative neoplasms. Cancer Med 9(24):9445\u20139453. https:\/\/doi.org\/10.1002\/cam4.3566","journal-title":"Cancer Med"},{"issue":"2","key":"6421_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.12375","volume":"162","author":"CN Harrison","year":"2013","unstructured":"Harrison CN, Mesa RA, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM (2013) Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol 162(2):229\u2013239. https:\/\/doi.org\/10.1111\/bjh.12375","journal-title":"Br J Haematol"},{"issue":"10","key":"6421_CR11","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA (2017a) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol 96(10):1653\u20131665. https:\/\/doi.org\/10.1007\/s00277-017-3082-y","journal-title":"Ann Hematol"},{"issue":"7","key":"6421_CR12","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA (2017b) Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 4(7):e317\u2013e324. https:\/\/doi.org\/10.1016\/S2352-3026(17)30088-1","journal-title":"Lancet Haematol"},{"issue":"3","key":"6421_CR13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/leu.2016.323","volume":"31","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T (2017c) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 31(3):775. https:\/\/doi.org\/10.1038\/leu.2016.323","journal-title":"Leukemia"},{"key":"6421_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.112717","volume":"254","author":"XY He","year":"2020","unstructured":"He XY, Wu LJ, Wang WX, Xie PJ, Chen YH, Wang F (2020) Amygdalin\u2014a pharmacological and toxicological review. J Ethnopharmacol 254:112717. https:\/\/doi.org\/10.1016\/j.jep.2020.112717","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"6421_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/1534735411423920","volume":"11","author":"M Horneber","year":"2012","unstructured":"Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2012) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11(3):187\u2013203. https:\/\/doi.org\/10.1177\/1534735411423920","journal-title":"Integr Cancer Ther"},{"issue":"2","key":"6421_CR16","first-page":"943","volume":"34","author":"J Huebner","year":"2014","unstructured":"Huebner J, Micke O, Muecke R, Buentzel J, Prott FJ, Kleeberg U, Senf B, Muenstedt K, PRIO (Working Group Prevention and Integrative Oncology of the German Cancer Society) (2014) User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German Comprehensive Cancer Center. Anticancer Res 34(2):943\u20138","journal-title":"Anticancer Res"},{"issue":"12","key":"6421_CR17","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1007\/s00277-023-05458-1","volume":"102","author":"S Koschmieder","year":"2023","unstructured":"Koschmieder S, Isfort S, Schulte C, Jacobasch L, Geer T, Reiser M, Koenigsmann M, Heinrich B, Wehmeyer J, von der Heyde E, Tesch H, Gr\u00f6schl B, Bachhuber P, Gro\u00dfer S, Pahl HL (2023) Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were na\u00efve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial. Ann Hematol 102(12):3383\u20133399. https:\/\/doi.org\/10.1007\/s00277-023-05458-1","journal-title":"Ann Hematol"},{"issue":"4","key":"6421_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3324\/haematol.2023.283987","volume":"110","author":"VY Ling","year":"2025","unstructured":"Ling VY, Heidel FH, Bywater MJ (2025) Pathogenesis and management of high molecular risk myeloproliferative neoplasms. Haematologica 110(4):863\u2013876. https:\/\/doi.org\/10.3324\/haematol.2023.283987","journal-title":"Haematologica"},{"key":"6421_CR19","doi-asserted-by":"crossref","unstructured":"Manz K, Heidel FH, Koschmieder S, Schlag R, Lipke J, Stegelmann F, Griesshammer M, Klausmann M, Crodel C, Hochhaus A, Schulz H, G\u00f6thert JR, Al-Ali H, Becker H, Reiter A, Kricheldorf K, Br\u00fcmmendorf TH, Hoffmann W, D\u00f6hner K, Isfort S (2024) Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment\u2014an intraindividual analysis by the German Study Group for MPN (GSG-MPN). Leukemia. In Press","DOI":"10.1182\/blood-2024-206143"},{"issue":"1","key":"6421_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer 109(1):68\u201376. https:\/\/doi.org\/10.1002\/cncr.22365","journal-title":"Cancer"},{"issue":"4","key":"6421_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","volume":"15","author":"RA Mesa","year":"2015","unstructured":"Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J (2015) Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk 15(4):214-221.e1. https:\/\/doi.org\/10.1016\/j.clml.2014.12.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6421_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN landmark survey. BMC Cancer 16:167. https:\/\/doi.org\/10.1186\/s12885-016-2208-2","journal-title":"BMC Cancer"},{"issue":"9","key":"6421_CR23","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.clml.2018.05.020","volume":"18","author":"R Mesa","year":"2018","unstructured":"Mesa R, Boccia RV, Grunwald MR, Oh ST, Colucci P, Paranagama D, Parasuraman S, Stein BL (2018) Patient-reported outcomes data from reveal at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the united States. Clin Lymphoma Myeloma Leuk 18(9):590\u2013596. https:\/\/doi.org\/10.1016\/j.clml.2018.05.020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"6421_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ctcp.2004.12.005","volume":"11","author":"A Molassiotis","year":"2005","unstructured":"Molassiotis A, Margulies A, Fernandez-Ortega P, Pud D, Panteli V, Bruyns I, Scott JA, Gudmundsdottir G, Browall M, Madsen E, Ozden G, Magri M, Selvekerova S, Platin N, Kearney N, Patiraki E (2005) Complementary and alternative medicine use in patients with haematological malignancies in Europe. Complement Ther Clin Pract 11(2):105\u2013110. https:\/\/doi.org\/10.1016\/j.ctcp.2004.12.005","journal-title":"Complement Ther Clin Pract"},{"issue":"1","key":"6421_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/hon.2429","volume":"36","author":"F Palandri","year":"2018","unstructured":"Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isidori A, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, Bonifacio M (2018) Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: results from an independent study. Hematol Oncol 36(1):285\u2013290. https:\/\/doi.org\/10.1002\/hon.2429","journal-title":"Hematol Oncol"},{"issue":"8","key":"6421_CR26","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41375-025-02646-y","volume":"39","author":"F Palandri","year":"2025","unstructured":"Palandri F, Breccia M, Elli EM, Latagliata R, Benevolo G, Morsia E, Tiribelli M, Cavazzini F, D\u2019Addio A, Tieghi A, Farina M, Cavalca F, Dedola A, Heidel FH, Palumbo GA, Rossi E, Branzanti F, De Stefano V (2025) Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea. Leukemia 39(8):1928\u20131936. https:\/\/doi.org\/10.1038\/s41375-025-02646-y","journal-title":"Leukemia"},{"issue":"11","key":"6421_CR27","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.bbmt.2019.07.001","volume":"25","author":"J Palmer","year":"2019","unstructured":"Palmer J, Kosiorek HE, Wolschke C, Fauble VDS, Butterfield R, Geyer H, Scherber RM, Dueck AC, Gathany A, Mesa RA, Kroger N (2019) Assessment of quality of life following allogeneic stem cell transplant for myelofibrosis. Biol Blood Marrow Transplant 25(11):2267\u20132273. https:\/\/doi.org\/10.1016\/j.bbmt.2019.07.001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"6421_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080854","volume":"8","author":"F Perner","year":"2019","unstructured":"Perner F, Perner C, Ernst T, Heidel FH (2019) Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells 8(8):854. https:\/\/doi.org\/10.3390\/cells8080854","journal-title":"Cells"},{"issue":"5","key":"6421_CR29","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41375-025-02569-8","volume":"39","author":"F Perner","year":"2025","unstructured":"Perner F, Pahl HL, Zeiser R, Heidel FH (2025) Malignant JAK-signaling: at the interface of inflammation and malignant transformation. Leukemia 39(5):1011\u20131030. https:\/\/doi.org\/10.1038\/s41375-025-02569-8","journal-title":"Leukemia"},{"issue":"4","key":"6421_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00520-010-0846-5","volume":"19","author":"SM Rausch","year":"2011","unstructured":"Rausch SM, Winegardner F, Kruk KM, Phatak V, Wahner-Roedler DL, Bauer B, Vincent A (2011) Complementary and alternative medicine: use and disclosure in radiation oncology community practice. Support Care Cancer 19(4):521\u20139. https:\/\/doi.org\/10.1007\/s00520-010-0846-5","journal-title":"Support Care Cancer"},{"issue":"2\u20133","key":"6421_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ctim.2004.09.006","volume":"12","author":"A Robinson","year":"2004","unstructured":"Robinson A, McGrail MR (2004) Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med 12(2\u20133):90\u201398. https:\/\/doi.org\/10.1016\/j.ctim.2004.09.006","journal-title":"Complement Ther Med"},{"key":"6421_CR32","unstructured":"S3-Leitlinie Leitlinienprogramm\u2014Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, Awmf): Komplement\u00e4rmedizin in der behandlung von Onkologischen Patientinnen, langversion 1.0, 2021, Awmf Registernummer: 032\/055ol"},{"key":"6421_CR33","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr., Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"issue":"1","key":"6421_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00277-021-04682-x","volume":"101","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Parasuraman S, Yu J, Shah A, Kumar S, Xi A, Harrison C (2022) Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Ann Hematol 101(1):131\u2013137. https:\/\/doi.org\/10.1007\/s00277-021-04682-x","journal-title":"Ann Hematol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06421-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06421-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06421-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:49:30Z","timestamp":1768927770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06421-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6421"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06421-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6957013\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"41"}}